Actively Recruiting
Pharmacokinetics and Pharmacodynamics of Oxytocin During Cesarean Delivery to Prevent Uterine Atony
Led by Stanford University · Updated on 2026-08-21
100
Participants Needed
2
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying oxytocins pharmacokinetics and pharmacodynamics during cesarean delivery to better understand its role in preventing uterine atony, a condition where the uterus fails to contract properly after childbirth. This phase 2 study focuses on parturients aged 18 to 50 experiencing term pregnancies and undergoing scheduled or unscheduled cesarean sections. The research aims to clarify why first-line oxytocin therapy sometimes fails to prevent excessive bleeding. Participants will receive a single intravenous dose of deuterium-labeled oxytocin 1 IU bolus during cesarean delivery, followed by a continuous infusion of standard oxytocin immediately after placental delivery. Blood samples will be collected at multiple time points within the first hour after delivery to measure both labeled and unlabeled oxytocin levels. Simultaneously, uterine tone will be assessed using a 0 to 10 scale to correlate oxytocin concentrations with uterine contraction strength. During the study, participants will have an additional IV catheter placed for blood sampling. Uterine tone scores will be recorded alongside blood draws until accurate assessment is no longer possible. Researchers will analyze plasma oxytocin concentrations and uterine tone scores to define oxytocins effects. The study involves intraoperative monitoring and sample collection, with no long-term follow-up beyond the cesarean delivery period.
CONDITIONS
Brief Title
Oxytocin Pharmacokinetics and Pharmacodynamics
Research Team
N
Naida M Cole, MD
S
Somayeh Mohammadi
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here